Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Artiva Biotherapeutics (ARTV) over the last 1 years, with Mar 2025 value amounting to $442,000.

  • Artiva Biotherapeutics' Gains from Investment Securities rose 1525.81% to $442,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $622,000, marking a year-over-year change of. This contributed to the annual value of $149,000 for FY2024, which is 207.19% up from last year.
  • Artiva Biotherapeutics' Gains from Investment Securities amounted to $442,000 in Q1 2025, which was up 1,239.39% from $33,000 recorded in Q4 2024.
  • In the past 5 years, Artiva Biotherapeutics' Gains from Investment Securities ranged from a high of $442,000 in Q1 2025 and a low of -$45,000 during Q4 2023.
  • For the 3-year period, Artiva Biotherapeutics' Gains from Investment Securities averaged around $73,571, with its median value being $33,000 (2024).
  • Data for Artiva Biotherapeutics' Gains from Investment Securities shows a peak YoY surged of 1,525.81% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Gains from Investment Securities stood at -$45,000 in 2023, then skyrocketed by 173.33% to $33,000 in 2024, then spiked by 1,525.81% to $442,000 in 2025.
  • Its last three reported values are $442,000 in Q1 2025, $33,000 for Q4 2024, and $38,000 during Q3 2024.